2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

bivalent antibody

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

4

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99391
    Telisotuzumab

    ABT-700

    		 c-Met/HGFR Apoptosis Cancer
    Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
    Telisotuzumab
  • HY-P99947
    Rimteravimab

    XVR011

    		 SARS-CoV Infection
    Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .
    Rimteravimab
  • HY-P99192
    Emibetuzumab

    LY2875358

    		 c-Met/HGFR Cancer
    Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .
    Emibetuzumab
  • HY-P99391A
    Telisotuzumab (powder)

    ABT-700 (powder)

    		 c-Met/HGFR Apoptosis Cancer
    Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
    Telisotuzumab (powder)
  • HY-155471
    IMP 245

    		Biochemical Assay Reagents Others
    IMP 245 is a symmetric di-HSG bivalent hapten. IMP 245 has low toxicity, high affinity binding to available antibodies and absence of cross reactivity or non-specific binding with body components .
    IMP 245
  • HY-155470
    IMP 243

    		Biochemical Assay Reagents Cancer
    IMP 243 is a symmetric di-HSG (histamine-succinyl-glycine) bivalent hapten containing a Tscg-Cys ligand and two HSG groups. IMP 243 can be radiolabeled with 99mTc-pertechnetate. IMP 243 can be conjugated to other peptides to design bispecific antibodies (bsMAbs) for cancer research .
    IMP 243
  • HY-155446
    di-DTPA-LTL

    		Others Inflammation/Immunology Cancer
    di-DTPA-LTL is a bivalent hapten based on tyrosine-containing polypeptide design. di-DTPA-LTL has good hydrophilia and biological distribution. di-DTPA-LTL is labeled with 111In (indium) and 131I (iodine). di-DTPA-LTL achieves tumor radioimmunoimaging in primary colorectal cancer patients with CEA by injecting a fixed low dose (5 mg) of bispecific antibody (anti-CEA x, anti-DTPA) and di-DTPA antigen peptide (labeled 111In) into the patients .
    di-DTPA-LTL

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: